Influence of Local Bone Status on Complications After Surgical Treatment of Proximal Humerus Fractures

NCT ID: NCT01143675

Last Updated: 2020-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

148 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-03-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate if poor bone quality increases the risk of specific types of treatment complications in patients with proximal humerus fractures treated with open reduction and angle-stable plates (Proximal Humeral Internal Locking System - PHILOS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

More than 70% of patients with a proximal humerus fracture are older than 60 years, up to three quarters are women and the incidence of low-energy fractures increases exponentially with age. The standard diagnostic method for classifying osteoporosis is the measurement of Bone Mineral Density at specific body sites - hip, vertebra or distal radius. Despite the fact that osteoporotic fractures are very frequent at the shoulder, no study investigated the correlation between local bone quality and fracture treatment at the proximal humerus.

There is a concern among the clinicians that osteoporotic bone in proximal humerus fractures increases the risk of treatment complications. However, to our knowledge this has not yet been evaluated in clinical studies. One major reason for this lack of studies is the fact that no standardized method exists for the determination of bone density at the proximal humerus.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Proximal Humeral Fractures Poor Bone Quality Treatment Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Radiologically confirmed closed fracture (within 10 days) of the proximal humerus
* All dislocated (mod. Neer) proximal humerus fractures except dislocated fractures of the greater and lesser tuberosity
* Primary fracture treatment with a PHILOS-plate
* Age equal greater than 50 and equal younger than 90 years
* Normal function of both shoulders (pre-trauma) according to age
* Monotrauma
* Willing and able to give written informed consent to participate in the study
* Willing and able to participate in the study follow-ups according to the CIP
* Willing and able to comply with the postoperative management program
* Able to understand and read country national language

Exclusion Criteria

* Open proximal humerus fractures
* Concomitant contralateral proximal humerus fracture
* Previous proximal humerus fracture on either side after the age of 25
* Time to operation \> 10 days
* Polytrauma
* Cuff-arthropathy of the contralateral proximal humerus
* Associated nerve or vessel injury
* Regular systemic therapy with corticosteroids due to chronic disease
* Legal incompetence
* Patient received radio- or chemotherapy prior to, during or within the last year
* Currently active cancer
* Recent history of substance abuse (i.e. recreational drugs, alcohol)
* Prisoner
* Currently involved in a pharmaceutical clinical study§
* Has a disease process that would preclude accurate evaluation (e.g. neuromuscular or rheumatic disease, significant psychiatric or metabolic disorders)
* Simultaneous participation in another orthopedic/surgical study with the same or another fracture has to be approved by the AOCID.
Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AO Clinical Investigation and Publishing Documentation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Franz Kralinger, MD

Role: PRINCIPAL_INVESTIGATOR

Medizinische Uni Innsbruck

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medizinische Uni Innsbruck

Innsbruck, Tyrol, Austria

Site Status

Queen Mary Hospital

Hong Kong, , China

Site Status

Klinikum rechts der Isar der TU München

Munich, Bavaria, Germany

Site Status

Ev. Diakoniewerk Friederikenstift

Hanover, Lower Saxony, Germany

Site Status

Campus Virchow-Klinikum, Charité

Berlin, , Germany

Site Status

Centre Hosp Univ Vaudois

Lausanne, Canton of Vaud, Switzerland

Site Status

Kantonsspital Winterthur

Winterthur, Canton of Zurich, Switzerland

Site Status

Universitätsspital Basel

Basel, , Switzerland

Site Status

Kantonsspital

Lucerne, , Switzerland

Site Status

Stadtspital Triemli

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria China Germany Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Goldhahn S, Kralinger F, Rikli D, Marent M, Goldhahn J. Does osteoporosis increase complication risk in surgical fracture treatment? A protocol combining new endpoints for two prospective multicentre open cohort studies. BMC Musculoskelet Disord. 2010 Nov 9;11:256. doi: 10.1186/1471-2474-11-256.

Reference Type DERIVED
PMID: 21062463 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.aofoundation.org

Non profit organization dedicated to improving the care of patients with musculoskeletal injuries and their sequelae through research, development, education and quality assurance in the principles, practice, and result of fracture treatment.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FFOB-Hum

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LPHP-Philos-PHN Conservative Treatment
NCT00205959 COMPLETED PHASE4